Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Camrelizumab plus nab-paclitaxel and carboplatin for advanced triple-negative breast cancer
ChiCTR2100046837Phase 4Recruiting
- Sponsor
- Henan Cancer Hospital
- Start
- Jun 2021
- Modality
- DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules, Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of camrelizumab, paclitaxel and carboplatin in triple-negative breast cancer (TNBC), sponsored by Henan Cancer Hospital. Primary endpoints: Progression-free survival and Overall survival. Started Jun 2021; status: recruiting.
02
Drugs
camrelizumabpaclitaxelcarboplatin
03
Conditions
triple-negative breast cancer (TNBC)
Beyond the preview
Go deeper on ChiCTR2100046837.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2100046837.